Last reviewed · How we verify
Hepatocellular carcinoma — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Hepatocellular carcinoma (Hepatocellular carcinoma) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hepatocellular carcinoma TARGET | Hepatocellular carcinoma | Assistance Publique - Hôpitaux de Paris | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hepatocellular carcinoma CI watch — RSS
- Hepatocellular carcinoma CI watch — Atom
- Hepatocellular carcinoma CI watch — JSON
- Hepatocellular carcinoma alone — RSS
Cite this brief
Drug Landscape (2026). Hepatocellular carcinoma — Competitive Intelligence Brief. https://druglandscape.com/ci/hepatocellular-carcinoma. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab